Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Large cohort study: Bevacizumab safe, effective for severe HHT bleeds

Key clinical point: Bevacizumab is safe and highly effective for HHT bleeding.

Major finding: Mean hemoglobin increased by 3.2 g/dL, ESS decreased by a mean of 3.4 points, red blood cell units transfused decreased by 82%

Study details: An international observational cohort study of 238 patients

Disclosures: Dr. Al-Samkari reported receiving research support and/or consulting fees from Agios, Dova, and Amgen.


Al-Samkari H et al. ISTH 2020. Abstract OC 09.2.